Alvotech Ordinary Shares

ALVO

Alvotech is a global biopharmaceutical company specializing in the development and manufacturing of high-quality biosimilar medicines. Focused on creating affordable alternatives to existing biologic treatments, Alvotech aims to enhance patient access to vital therapies across various therapeutic areas.

$5.44 -0.03 (-0.55%)

Company News

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm • December 6, 2025

Rosen Law Firm is investigating potential securities claims for Alvotech shareholders following an FDA Complete Response Letter for their Biologics License Application, which caused a significant stock price drop.

ALVOW

Alvotech Shares Plunge 33% After FDA Flags Issues

Benzinga • Vandana Singh • November 3, 2025

Biotech company Alvotech received a complete response letter from the FDA for its biosimilar drug AVT05, citing manufacturing facility deficiencies. The company's stock dropped significantly, and it revised its 2025 revenue and EBITDA projections downward.

ALVOW JNJ

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

Zacks Investment Research • Zacks Equity Research • June 25, 2024

Here is how Alvotech (ALVO) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.

ATOS

Why Shares of Alvotech Are Jumping Friday

The Motley Fool • [email protected] (Jim Halley) • June 30, 2023

The biosimilar drug company's shares rebounded a day after it announced that the FDA had dealt it setback.

ABBV